These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

665 related items for PubMed ID: 28207888

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S, Menzies R, Chiu C, Toms C, Blyth CC, Krause V, McIntyre P.
    Clin Infect Dis; 2017 Jan 15; 64(2):175-183. PubMed ID: 27986682
    [Abstract] [Full Text] [Related]

  • 3. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF.
    Vaccine; 2013 Dec 16; 31(52):6232-8. PubMed ID: 24176490
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
    Lepoutre A, Varon E, Georges S, Dorléans F, Janoir C, Gutmann L, Lévy-Bruhl D, Microbiologists of Epibac, ORP Networks.
    Vaccine; 2015 Jan 03; 33(2):359-66. PubMed ID: 25448105
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Expansion of serotype coverage in the universal pediatric vaccination calendar: short-term effects on age- and serotype-dependent incidence of invasive pneumococcal clinical presentations in Madrid, Spain.
    Picazo J, Ruiz-Contreras J, Casado-Flores J, Negreira S, García-de-Miguel MJ, Hernández-Sampelayo T, Otheo E, Méndez C, HERACLES Study Group.
    Clin Vaccine Immunol; 2013 Oct 03; 20(10):1524-30. PubMed ID: 23925887
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.
    Ben-Shimol S, Greenberg D, Givon-Lavi N, Schlesinger Y, Somekh E, Aviner S, Miron D, Dagan R.
    Vaccine; 2014 Jun 05; 32(27):3452-9. PubMed ID: 24690148
    [Abstract] [Full Text] [Related]

  • 12. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality.
    Harboe ZB, Dalby T, Weinberger DM, Benfield T, Mølbak K, Slotved HC, Suppli CH, Konradsen HB, Valentiner-Branth P.
    Clin Infect Dis; 2014 Oct 15; 59(8):1066-73. PubMed ID: 25034421
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
    Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MP, Miller E.
    Lancet Infect Dis; 2015 May 15; 15(5):535-43. PubMed ID: 25801458
    [Abstract] [Full Text] [Related]

  • 17. Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012.
    Demczuk WH, Martin I, Griffith A, Lefebvre B, McGeer A, Lovgren M, Tyrrell GJ, Desai S, Sherrard L, Adam H, Gilmour M, Zhanel GG, Toronto Bacterial Diseases Network, Canadian Public Health Laboratory Network.
    Can J Microbiol; 2013 Dec 15; 59(12):778-88. PubMed ID: 24313450
    [Abstract] [Full Text] [Related]

  • 18. Impact of introduction of conjugate vaccines in the vaccination schedule on the incidence of pediatric invasive pneumococcal disease requiring hospitalization in Madrid 2007 to 2011.
    Picazo J, Ruiz-Contreras J, Casado-Flores J, Giangaspro E, García-de-Miguel MJ, Hernández-Sampelayo T, Otheo E, Méndez C, Heracles Study Group.
    Pediatr Infect Dis J; 2013 Jun 15; 32(6):656-61. PubMed ID: 23249906
    [Abstract] [Full Text] [Related]

  • 19. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.
    Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, Petit S, Zansky SM, Harrison LH, Reingold A, Miller L, Scherzinger K, Thomas A, Farley MM, Zell ER, Taylor TH, Pondo T, Rodgers L, McGee L, Beall B, Jorgensen JH, Whitney CG.
    Lancet Infect Dis; 2015 Mar 15; 15(3):301-9. PubMed ID: 25656600
    [Abstract] [Full Text] [Related]

  • 20. Serotypes and clones causing invasive pneumococcal disease before the use of new conjugate vaccines in Catalonia, Spain.
    Muñoz-Almagro C, Ciruela P, Esteva C, Marco F, Navarro M, Bartolome R, Sauca G, Gallés C, Morta M, Ballester F, Raga X, Selva L, Catalan study group of invasive pneumococcal disease.
    J Infect; 2011 Aug 15; 63(2):151-62. PubMed ID: 21679725
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.